Lysosomal Storage Disease: Revealing Lysosomal Function and Physiology

被引:170
作者
Parkinson-Lawrence, Emma J. [1 ]
Shandala, Tetyana
Prodoehl, Mark
Plew, Revecca
Borlace, Glenn N.
Brooks, Doug A.
机构
[1] Univ S Australia, Cell Biol Dis Res Grp, Sansom Inst Hlth Res, Div Hlth Sci, Adelaide, SA 5001, Australia
基金
英国医学研究理事会; 澳大利亚研究理事会;
关键词
I-CELL DISEASE; CHEDIAK-HIGASHI-SYNDROME; MULTIPLE SULFATASE DEFICIENCY; NIEMANN-PICK; MOUSE MODEL; ACID SPHINGOMYELINASE; TARGETED DISRUPTION; GAUCHER-DISEASE; SKELETAL-MUSCLE; FABRY-DISEASE;
D O I
10.1152/physiol.00041.2009
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The discovery over five decades ago of the lysosome, as a degradative organelle and its dysfunction in lysosomal storage disorder patients, was both insightful and simple in concept. Here, we review some of the history and pathophysiology of lysosomal storage disorders to show how they have impacted on our knowledge of lysosomal biology. Although a significant amount of information has been accrued on the molecular genetics and biochemistry of lysosomal storage disorders, we still do not fully understand the mechanistic link between the storage material and disease pathogenesis. However, the accumulation of undegraded substrate(s) can disrupt other lysosomal degradation processes, vesicular traffic, and lysosomal biogenesis to evoke the diverse pathophysiology that is evident in this complex set of disorders.
引用
收藏
页码:102 / 115
页数:14
相关论文
共 126 条
[1]   Plasma and metabolic abnormalities in Gaucher's disease [J].
Aerts, JMFG ;
Hollak, CEM .
BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (04) :691-709
[2]  
AGHION A, 1934, FM PARIS
[3]   Renal pathology in Fabry disease [J].
Alroy, J ;
Sabnis, S ;
Kopp, JB .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (06) :S134-S138
[4]  
AULA P, 1975, VIRCHOWS ARCH B, V18, P263
[5]   Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model [J].
Balreira, A ;
Lacerda, L ;
Miranda, CS ;
Arosa, FA .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (05) :667-676
[6]   Gastrointestinal manifestations of Fabry disease: Clinical response to enzyme replacement therapy [J].
Banikazemi, M ;
Ullman, T ;
Desnick, RJ .
MOLECULAR GENETICS AND METABOLISM, 2005, 85 (04) :255-259
[7]   Cardiac and vascular hypertrophy in Fabry disease: Evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition [J].
Barbey, F ;
Brakch, N ;
Linhart, A ;
Rosenblatt-Velin, N ;
Jeanrenaud, X ;
Qanadli, S ;
Steinmann, B ;
Burnier, M ;
Palecek, T ;
Bultas, J ;
Hayoz, D .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (04) :839-844
[8]   Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: A possible mechanism for deregulation of T lymphocyte activation [J].
Barrat, FJ ;
Le Deist, F ;
Benkerrou, M ;
Bousso, P ;
Feldmann, J ;
Fischer, A ;
de Saint Basile, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8645-8650
[9]   MULTIPLE DEFICIENCY OF MUCOPOLYSACCHARIDE SULFATASES IN MUCOSULFATIDOSIS [J].
BASNER, R ;
FIGURA, KV ;
GLOSSL, J ;
KLEIN, U ;
KRESSE, H ;
MLEKUSCH, W .
PEDIATRIC RESEARCH, 1979, 13 (12) :1316-1318
[10]   A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome) [J].
Bhaumik, M ;
Muller, VJ ;
Rozaklis, T ;
Johnson, L ;
Dobrenis, K ;
Bhattacharyya, R ;
Wurzelmann, S ;
Finamore, P ;
Hopwood, JJ ;
Walkley, SU ;
Stanley, P .
GLYCOBIOLOGY, 1999, 9 (12) :1389-1396